GlassScriptPhysician profile
Jeffry D Bieber
NPI 1831294891
$27,183.06
in general payments reported to CMS, 2019-2025
34 companies · $1,925 in 2025
The $1,925 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $1,262 · 2021: $1,172 · 2022: $1,023 · 2023: $1,400 · 2024: $2,099 · 2025: $1,925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,332 · Education: $93.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,331.63 |
| Education | $93.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18,667.67 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $2,526.99 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Pfizer INC. | $1,069.70 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $684.35 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $668.82 | 2019-2025 | |
| Janssen Biotech, INC. | $663.94 | 2019-2025 | Tremfya, Stelara, Remicade |
| Glaxosmithkline, LLC. | $454.31 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $282.24 | 2019-2024 | Taltz |
| Ucb, INC. | $182.12 | 2020-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.61 | 2020-2023 | Ofev |
| Mallinckrodt Hospital Products INC. | $160.92 | 2021-2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $153.65 | 2019-2023 | Uptravi |
| Sandoz INC. | $147.04 | 2024-2025 | Hyrimoz |
| Aurinia Pharma U.S., INC. | $135.48 | 2021-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $134.31 | 2019-2025 | Strensiq, Ultomiris |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $132.98 | 2024-2025 | Hadlima, Renflexis |
| Celgene Corporation | $107.91 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $103.73 | 2024 | Arcalyst |
| Sobi, INC | $102.87 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $88.12 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $71.46 | 2019 | |
| Kyowa Kirin, INC. | $70.08 | 2023 | Crysvita |
| Fresenius Kabi USA, LLC | $70.05 | 2023-2025 | Idacio |
| Radius Health, INC. | $67.99 | 2019-2024 | Tymlos |
| Genentech USA, INC. | $57.71 | 2019-2025 | Gazyva |
| Horizon Therapeutics Plc | $49.40 | 2020-2022 | |
| United Therapeutics Corporation | $43.71 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $28.38 | 2023 | Arcalyst |
| Mallinckrodt Enterprises LLC | $19.58 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.29 | 2019 | |
| Scilex Pharmaceuticals INC. | $14.96 | 2024 | |
| Genzyme Corporation | $14.40 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Zyla Life Sciences, INC. | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffry Bieber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.